ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 原著論文

臨床試験・研究対象者保護法制の国際比較─国際規範,日本,米国,欧州,韓国,台湾,南アフリカ─

https://repo.qst.go.jp/records/48818
https://repo.qst.go.jp/records/48818
eff59cd3-e3aa-4c38-a221-42a9f93aa1f1
Item type 学術雑誌論文 / Journal Article(1)
公開日 2018-04-26
タイトル
タイトル 臨床試験・研究対象者保護法制の国際比較─国際規範,日本,米国,欧州,韓国,台湾,南アフリカ─
言語
言語 jpn
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 栗原, 千絵子

× 栗原, 千絵子

WEKO 491688

栗原, 千絵子

Search repository
栗原 千絵子

× 栗原 千絵子

WEKO 491689

en 栗原 千絵子

Search repository
抄録
内容記述タイプ Abstract
内容記述 Background:Japanese Clinical Research Act was enacted in April 2017 and this Act covers clinical trial of drug, device, and regenerative medicine product, except the trials aiming at marketing authorization under the Pharmaceuticals and Medical Devices Act (PMD Act). The trigger of this Act was a substantial number of misconducts of industry-sponsored clinical research.
Objectives:To clarify commonalities and differences among Japanese regulations for clinical trials and research involving human subjects in comparison with international standards and other countries’ regulations, to identify future directions to go ahead, concerning this new Act in Japan.
Method:Literature review and comparative analysis of regulations and/or standards of clinical trial and research of international organizations; Japan; the United States; Europe; South Korea; Taiwan; and South Africa.
Findings:In Japan, GCP (good clinical practice) Ordinance under the PMD Act covers only clinical trials aiming at new product/indication authorization. On the other hand, in other countries, GCP under pharmaceutical laws covers a wider range of clinical trials. International organizations and other countries have developed a wider range of laws and standards for human research not only in medical but also in social or behavioral research, as well as for the use or retention of human samples or information, some of which are referred to as biobank and health database.
Conclusion:Product promotion-oriented commercial sponsoring research by industries should be changed to aim at “global health” for the people who need the results of medical development. To pursue this idea, the Japanese new Clinical Research Act and related regulations and policies should be reformed to establish legal protection of the rights of human subjects, and on this basis clinical trials of medical products should be covered by GCP under the PMD Act, following the international standard.
書誌情報 臨床評価

巻 45, 号 3, p. 649-665, 発行日 2017-11
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 23:23:59.223719
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3